Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trametinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 17/20 | 0.98 |
| ▸ | MAP2K2 known ✓ | P36507 | 2/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.37 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trametinib SCHEMBL29355100 | 0.99 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL170938 | 0.99 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL29363416 | 0.99 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419395 | 0.98 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL21048481 | 0.98 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419392 | 0.98 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL30301264 | 0.98 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL30035834 | 0.98 | MAP2K1 (0.98) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| Trametinib SCHEMBL1419017 | 0.98 | MAP2K1 (0.97) | MAP2K1MAP2K2ABCB1NOX4PIK3CA | |
| SCHEMBL26815709 | 0.97 | MAP2K1 (0.96) | MAP2K1MAP2K2ABCB1NOX4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380362-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2022-12-01 | — | — | US | disclosed |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| US-20180273531-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2018-09-27 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20150183812-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8835443-B2 | Pyrimidine compound and medical use thereof | JAPAN TOBACCO INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2298768-B9 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | JAPAN TOBACCO INC (JP) | 2013-04-24 | — | — | EP | disclosed |
| EP-2298768-B1 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | JAPAN TOBACCO INC (JP) | 2012-11-14 | — | — | EP | disclosed |
| EP-2298768-A1 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | Japan Tobacco, Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100240613-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7378423-B2 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2008-05-27 | — | — | US | disclosed |
| EP-1894932-A1 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | Japan Tobacco, Inc. (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1761528-B1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-20060014768-A1 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | JAPAN TOBACCO INC. (JP) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380362-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | MAP2K1 1079/4885MAP2K2 1130/4885ABCB1 295/4885 |
| US-20180273531-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | MAP2K1 1079/4885MAP2K2 1130/4885ABCB1 295/4885 |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | MAP2K1 1079/4885MAP2K2 1130/4885ABCB1 295/4885 |
| US-20100240613-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | MAP2K1 1079/4885MAP2K2 1130/4885ABCB1 295/4885 |
| US-20060014768-A1 | Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction | CDKN1A, CDK2, CDC25A | MAP2K1 69/4885MAP2K2 66/4885ABCB1 1473/4885 |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | MAP2K1 1079/4885MAP2K2 1130/4885ABCB1 295/4885 |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | MAP2K1 1079/4885MAP2K2 1130/4885ABCB1 295/4885 |
| US-20150183812-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | MAP2K1 1079/4885MAP2K2 1130/4885ABCB1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.